Overcoming "aspirin resistance" in MPN

Blood

Volumn 119, Issue 15, 2012, Pages 3377-3378

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; THROMBOXANE A2;

ANTICOAGULANT THERAPY; BLOOD LEVEL; BONE MARROW CANCER; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; ENZYME INACTIVATION; HUMAN; MEDICAL PRACTICE; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NOTE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTHEMIA;

EID: 84859809994     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-406645     Document Type: Note

References (10)

1. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595-3603.
2. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. NEngl J Med. 2001;345(25):1809-1817.
3. Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010;115(5):1054-1061.
4. Henry P, Vermillet A, Boval B, et al. 24-hour timedependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011;105(2):336-344.
5. Di Minno MN, Lupoli R, Palmieri NM, Russolillo A, Buonauro A, Di Minno G. Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thromb Res. 2012;129(3):341-344.
6. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost. 2011;9(1):185-191.
7. Snoep JD, HovensMM,Eikenboom JC, van derBomJG, HuismanMV.Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167(15):1593-1599. (Pubitemid 47280339)
8. Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J. 2006;151(5):976.e7-11.
9. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011;106(3):491-499.
10. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.